Volume 2.19 | May 18

Mesenchymal Cell News 2.19, May 18, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


In Vitro Transformation of Mesenchymal Stem Cells Induces Gradual Genomic Hypomethylation
Researchers hypothesized that DNA hypomethyation would occur during step-wise transformation of mesenchymal stem cells and could be a model to investigate the mechanism of global hypomethylation in cancer. [Carcinogenesis]

MethoCult® Express Video  
Learn about the benefits of MethoCult® Express
for cord blood samples

by STEMCELL Technologies


Stem Cells Restore Tissue Affected By ALI
Human stem cells administered intravenously can restore alveolar epithelial tissue to a normal function in a novel ex vivo perfused human lung after E. coli endotoxin-induced acute lung injury (ALI), according to research from the University of California San Francisco. [Press release from Medical News Today discussing research presented at the ATS 2010 International Conference]

Transplanted Adult Stem Cells Provide Lasting Help to Injured Hearts
Human adult stem cells injected around the damage caused by a heart attack survived in the heart and improved its pumping efficiency for a year in a mouse model, researchers reported. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in Circulation Research]

MesenCult®-XF Medium  
Culture Human Mesenchymal Stem Cells in
Serum-Free MesenCult®-XF

by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Human CD34+ Cells in Experimental Myocardial Infarction. Long-Term Survival, Sustained Functional Improvement, and Mechanism of Action
Researchers sought to track the fate of injected human CD34+ cells in the hearts of severe combined immune deficiency mice after experimental myocardial infarction and to determine the mechanisms of action. [Circulation]

Isolation and Characterization of Endosteal Niche Cell Populations that Regulate Hematopoietic Stem Cells
Altogether, these data suggest that multiple subsets of osteoblasts and mesenchymal progenitor cells constitute the endosteal niche and regulate hematopoietic stem cells in adult bone marrow. [Blood]

CD117 and Stro-1 Identify Osteosarcoma Tumor-Initiating Cells Associated with Metastasis and Drug Resistance
In this study, researchers have identified mouse and human osteosarcoma tumor-initiating cells using mesenchymal stem cell markers CD117 and Stro-1. [Cancer Res]

Mesenchymal Stem Cells Inhibition of Chronic Ethanol-Induced Oxidative Damage Via Upregulation of Phosphatidylinositol-3-Kinase/Akt and Modulation of Extracellular Signal-Regulated Kinase 1/2 Activation in PC12 Cells and Neurons
In the present study, researchers assessed the potential effects of mesenchymal stem cell conditioned medium against chronic ethanol-associated damage on PC12 cells and primary cortical neurons. [Neuroscience]

Human Osteoblasts Derived from Mesenchymal Stem Cells Express Adipogenic Markers Upon Coculture with Bone Marrow Adipocytes
Researchers cocultured adipocytes with osteoblasts derived from mesenchymal stem cells in the absence of direct cell contact and then analyzed gene expression changes in the osteoblastic population by using real-time reverse transcription polymerase chain reaction. [Differentiation]

Microporation is a Valuable Transfection Method for Efficient Gene Delivery into Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells
In this study, researchers applied microporation technology as a novel electroporation technique to introduce enhanced green fluorescent protein and brain-derived neurotrophic factor plasmid DNA into human umbilical cord blood-derived mesenchymal stem cells (MSCs) with significant efficiency, and investigated the stem cell potentiality of engineered MSCs through their phenotypes, proliferative capacity, ability to differentiate into multiple lineages, and migration ability towards malignant glioma cells. [BMC Biotechnol]


Mesoblast to Acquire Angioblast Systems Inc.
Australia’s regenerative medicine company, Mesoblast Limited, announced that it will acquire its United States associate company, Angioblast Systems, Inc. Additionally, Mesoblast announced it has completed a capital raising of $37 million to fund the acquisition and advance operations of the expanded Mesoblast Group. [Mesoblast Ltd. Press Release]

Osiris Therapeutics Reports First Quarter 2010 Financial Results
Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced its results for the first quarter of fiscal 2010. [Osiris Therapeutics, Inc. Press Release]

Vitro Announces Open Letter to Its Shareholders: Current Results and Future Prospects
Vitro Diagnostics, Inc., dba Vitro Biopharma, announced an open letter to its shareholders. [The Wall Street Journal]


Personal Gene-Testing Companies Need U.S. Clearance, FDA Says
Gene-test kits that promise to tell consumers their risk of Alzheimer’s disease, breast cancer and numerous illnesses must be approved by regulators whether the tests are sold online or in stores, a U.S. official said. [Food and Drug Administration, United States]

NIH Starts to Flesh out Drug Development Program
Lawmakers began discussing the details of a newly created drug development program at the National Institutes of Health (NIH). NIH Director Francis Collins told a Senate panel that he’s eager to get started-once the program has a budget. [National Institutes of Health, United States]

Statement by HHS Secretary Kathleen Sebelius and NIH Director Francis Collins Regarding the President’s Intent to Appoint Dr. Harold Varmus as Director of the National Institute of Cancer at the National Institutes of Health [National Institutes of Health, United States]

Notice of Funding Opportunity for a Cell Characterization Core for the National Heart, Lung and Blood Institute Progenitor Cell Biology Consortium (NOT-HL-10-109) [National Institutes of Health, United States]

Notice of Intent to Publish Request for Applications for the Blood and Marrow Transplant Clinical Trials Network Data Coordinating Center (U10) (NOT-HL-10-108) [National Institutes of Health, United States]

Enhancing Peer Review: Expectation for Service on NIH Peer Review and Advisory Groups (NOT-OD-10-089) [National Institutes of Health, United States]

Request for Information: Scientific and Regulatory Issues to be Explored at an Upcoming Pluripotent Stem Cell Workshop Involving NIH and FDA (NOT-NS-10-016) [National Institutes of Health, United States]

Drug Safety and Risk Management Advisory Committee; Notice of Meeting (Docket No. FDA-2010-N-0001) [Food and Drug Administration, United States]

Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Patient Information Prototypes (Docket No. FDA-2010-N-0184) [Food and Drug Administration, United States]


16th Annual International Society for Cellular Therapy (ISCT) Meeting
May 23-26, 2010
Philadelphia, United States

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – European Union 2010
June 13-17, 2010
Galway, Ireland

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

United Kingdom National Stem Cell Network (UKNSCN) 3rd Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

5th World Congress on Preventative and Regenerative Medicine (WCRM) 2010
October 5-7, 2010
Hannover, Germany

2010 American Society for Matrix Biology (ASMB) Meeting
October 24-27, 2010
Charleston, United States

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – North America 2010 Annual Conference
December 5-8, 2010
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Sr. Product Support and Training Specialist (CardianBCT)

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Mesenchymal Cell News.

Visit here to post your career opportunities.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Learn more about Mesenchymal Cell News: Archives  |  Events  |  Subscribe  |  Contact Us